STAT November 11, 2024
Elaine Chen

Emraclidine was a centerpiece of the company’s purchase of Cerevel Therapeutics

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda
The financial burden of drug shortages: 7 study takeaways
What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices
AI In Healthcare: A New Era Of Personalized Patient Care

Share This Article